IHM
Iguana Healthcare Management Portfolio holdings
AUM
$133M
This Quarter Return
+10.94%
1 Year Return
+45.66%
3 Year Return
+127.07%
5 Year Return
–
10 Year Return
–
AUM
$151M
AUM Growth
+$151M
(-13%)
Cap. Flow
-$28M
Cap. Flow
% of AUM
-18.49%
Top 10 Holdings %
Top 10 Hldgs %
41.58%
Holding
82
New
16
Increased
10
Reduced
28
Closed
20
Top Buys
| 1 |
Humana
HUM
|
$5.58M |
| 2 |
MYOK
MyoKardia, Inc. Common Stock
MYOK
|
$2.11M |
| 3 |
Supernus Pharmaceuticals
SUPN
|
$1.99M |
| 4 |
AKCA
Akcea Therapeutics, Inc. Common Stock
AKCA
|
$1.74M |
| 5 |
Puma Biotechnology
PBYI
|
$1.73M |
Top Sells
| 1 |
ALXN
Alexion Pharmaceuticals Inc
ALXN
|
$5.61M |
| 2 |
AET
Aetna Inc
AET
|
$4.53M |
| 3 |
Eli Lilly
LLY
|
$3.42M |
| 4 |
Glaukos
GKOS
|
$3.3M |
| 5 |
XLRN
Acceleron Pharma Inc.
XLRN
|
$2.61M |
Sector Composition
| 1 | Healthcare | 82.78% |
| 2 | Energy | 0.61% |
| 3 | Financials | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
Esperion Therapeutics
ESPR
$448M
| $10.9M | 7.08% |
165,000
+15,000
| +10% | +$988K |
|
|
CELG
2
DELISTED
Celgene Corp
CELG
| $7.83M | 5.1% |
75,000
| – | – |
|
|
IMMU
3
DELISTED
Immunomedics Inc
IMMU
| $7.27M | 4.74% |
450,000
-50,000
| -10% | -$808K |
|
4
Biogen
BIIB
$19.4B
| $7.01M | 4.56% |
22,000
+2,000
| +10% | +$637K |
|
|
5
Humana
HUM
$36.5B
| $5.58M | 3.64% |
+22,500
| New | +$5.58M |
|
|
AERI
6
DELISTED
Aerie Pharmaceuticals, Inc.
AERI
| $5.08M | 3.31% |
85,000
-15,000
| -15% | -$896K |
|
7
Cigna
CI
$80.3B
| $5.08M | 3.31% |
25,000
-1,500
| -6% | -$305K |
|
|
GBT
8
DELISTED
Global Blood Therapeutics, Inc.
GBT
| $4.92M | 3.2% |
125,000
| – | – |
|
9
AbbVie
ABBV
$372B
| $4.84M | 3.15% |
50,000
-15,000
| -23% | -$1.45M |
|
10
Merck
MRK
$210B
| $4.5M | 2.93% |
80,000
+5,000
| +7% | +$281K |
|
11
Abbott
ABT
$231B
| $4.28M | 2.79% |
75,000
-10,000
| -12% | -$571K |
|
|
CLVS
12
DELISTED
Clovis Oncology, Inc.
CLVS
| $4.08M | 2.66% |
60,000
-20,000
| -25% | -$1.36M |
|
13
AnaptysBio
ANAB
$569M
| $4.03M | 2.62% |
40,000
-10,000
| -20% | -$1.01M |
|
|
KTWO
14
DELISTED
K2M Group Holdings, Inc
KTWO
| $3.15M | 2.05% |
175,000
-25,000
| -13% | -$450K |
|
15
Bristol-Myers Squibb
BMY
$96B
| $3.06M | 2% |
50,000
-5,000
| -9% | -$306K |
|
|
SRRA
16
DELISTED
Sierra Oncology, Inc. Common Stock
SRRA
| $2.98M | 1.94% |
800,000
+200,000
| +33% | +$746K |
|
|
TSRO
17
DELISTED
TESARO, Inc.
TSRO
| $2.9M | 1.89% |
35,000
+10,000
| +40% | +$829K |
|
18
Karyopharm Therapeutics
KPTI
$61.7M
| $2.88M | 1.88% |
300,000
-100,000
| -25% | -$960K |
|
|
DERM
19
DELISTED
Dermira, Inc.
DERM
| $2.78M | 1.81% |
100,000
-25,000
| -20% | -$695K |
|
|
JUNO
20
DELISTED
Juno Therapeutics, Inc.
JUNO
| $2.74M | 1.79% |
60,000
-15,000
| -20% | -$686K |
|
21
Zimmer Biomet
ZBH
$21B
| $2.72M | 1.77% |
22,500
-7,500
| -25% | -$905K |
|
22
Sangamo Therapeutics
SGMO
$157M
| $2.46M | 1.6% |
150,000
-50,000
| -25% | -$820K |
|
|
XENT
23
DELISTED
Intersect ENT, Inc
XENT
| $2.43M | 1.58% |
75,000
-15,000
| -17% | -$486K |
|
24
Danaher
DHR
$147B
| $2.32M | 1.51% |
25,000
-10,000
| -29% | -$928K |
|
25
Ultragenyx Pharmaceutical
RARE
$2.89B
| $2.32M | 1.51% |
50,000
| – | – |
|